RFK Jr.'s vaccine committee votes on new RSV immunization, flu shots
The Centers for Disease Control and Prevention's influential panel of vaccine advisers Thursday approved updated recommendations for a new shot for respiratory syncytial virus, or RSV. It is also set to vote on recommendations for this year's influenza vaccine.
Their votes mark the panel's first official move after Health and Human Services Secretary Robert F. Kennedy Jr. fired the committee's experts and replaced them with his own picks earlier this month.
Votes by the panel are closely watched by health authorities because they are tied to federal policies and programs that enable access to vaccines, including requirements for insurance coverage and funding to provide shots for uninsured children.
Other vaccines are also being discussed by the panel, but not voted on, including those for COVID-19, chikungunya and anthrax.
Kennedy's new committee also announced Wednesday that it would start a renewed review of all recommended pediatric vaccines, over fears about the "cumulative effect" that the shots could be having on children. That includes weighing changes to recommendations for hepatitis B and measles vaccines given early in life.
The American Academy of Pediatrics denounced the move as sowing distrust in safe and effective immunizations, and warned Wednesday against curbing hepatitis B recommendations.
"Secretary Kennedy has given this committee a clear mandate to use evidence-based medicine when making vaccine recommendations, and that is what we will do. Vaccines are not all good or bad," Dr. Martin Kulldorff, the panel's chair, said Wednesday.
RSV shot
An RSV vaccine during pregnancy and another antibody shot called clesrovimab that can be given to newborns have previously been approved by the Food and Drug Administration and recommended by the CDC to prevent the disease.
The committee Thursday voted by a majority — five in favor, two against — to recommend a shot for newborns, branded as Enflonsia by Merck, adding another option to the already approved immunizations.
Two of the panel's new members — Retsef Levi, an operations management professor at the Massachusetts Institute of Technology, and Vicki Pebsworth, the research director of a group focused on preventing vaccine injuries and deaths — voted against recommendations for the shot.
Pebsworth said she worried about coadministration of the shot with other childhood vaccines, despite data presented by the CDC's Vaccine Safety Datalink showing that RSV antibody shots being given alongside other vaccines are not resulting in a safety risk.
Levi said that he was uncomfortable with clinical trial data he claimed suggested that deaths could be more frequent after use of the shots. He cited his experience as a parent, saying that "as a father, I can feel that I would be concerned."
"I don't feel this is ready to be administered to all healthy babies. I think we should take a more precautionary approach to this," Levi said.
That was at odds with reviews by the CDC and FDA, which did not turn up evidence of this risk. An FDA official told the panel that the death rates — 0.3% versus 0.2% — were not significant, and that careful reviews of the deaths concluded that their causes were not related to the drug.
Another panel member, Dr. Cody Meissner of Dartmouth University, disagreed with Levi, warning that 80% of children hospitalized with RSV are healthy with no underlying conditions.
Meissner had previously participated in the deliberations of the committee's work group as an outside adviser, before Kennedy purged its voting members.
"The work group has spent an enormous amount of time, the FDA has spent an enormous effort looking at safety and efficacy, and it is simply not an issue here," he said.
Flu vaccines
The panel is also expected to vote on updated recommendations for influenza vaccines for the coming season, usually a routine annual affair for the committee before Kennedy's purge.
This year is different also because Kennedy's committee is now scheduled to vote on vaccines that use thimerosal, a preservative used in a small handful of shots that has been the subject of debunked claims about risks for autism and other neurodevelopmental disorders.
Thursday's vote on thimerosal is scheduled to follow a presentation from Lyn Redwood, the former head of a group founded by Kennedy that has lobbied against vaccine authorizations and requirements. The group has been hired to work in the agency's vaccine safety office.
Young Cuban girl asks Trump to lift travel ban stopping her from joining mom in U.S.
Supreme Court allows South Carolina to block Medicaid funds from Planned Parenthood
Hegseth gets defensive over initial assessments about Trump's Iran nuclear sites strikes
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Premier acquires healthcare technology firm IllumiCare
Premier has expanded its clinical decision support (CDS) capabilities with the acquisition of healthcare technology firm IllumiCare, known for its Electronic Medical Record (EMR)-agnostic platform. This platform integrates clinical and financial data to aid providers in making cost-effective clinical decisions. The financial details of the transaction have not been disclosed. IllumiCare is based in the US and helps improve clinical decisions by providing real-time data on treatment expenses. Its flagship product identifies inpatient medication and diagnostic use that may not benefit patients, based on medical standards, and reveals the actual supply costs to the ordering provider. This approach encourages interventions in formulary and order sets and delivers targeted 'nudges' to clinicians at the point of care. Premier Performance Services president David Zito said: 'IllumiCare's real-time cost attribution capabilities will be a game changer, differentiating Premier in a competitive CDS market with a smarter, more robust CDS solution. 'Together, we can help create financial efficiencies for virtually any provider, in any clinical setting, while helping them deliver care that is better and safer for patients.' The acquisition is set to enhance Premier's existing CDS technology, further enabling health systems and clinically integrated networks to reduce care gaps, enhance coding accuracy, optimise clinical trial recruitment, support outpatient risk capture, and succeed using value-based payment models. Starting this summer, Premier plans to market the acquired solution under its Stanson Health brand. IllumiCare CEO G.T. LaBorde said: 'We want providers focused on the patient while technology works behind the scenes to point out the ancillary effects of choices when they are directly relevant. Our combined solution will offer providers a more robust, turnkey solution, with a demonstrated return on investment of up to ten to one.' "Premier acquires healthcare technology firm IllumiCare" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Uterine cancer projected to rise in US, Black women likely to be hit hardest
Uterine cancer cases in the U.S. will rise significantly by 2050, with Black women three times more likely to die from it, a study from the American Association for Cancer Research projects. Uterine cancer is the most common gynecologic cancer in the U.S. In 2024, there were almost 70,000 cases, according to the National Cancer Institute. Over the past 30 years, uterine cancer cases and deaths have jumped. NCI data shows that between 2015 and 2019, there was about a 2% increase in new cases per year, the highest for any cancer in women. FDA considers issuing proposed rule to ban formaldehyde in hair straightening products Researchers at Columbia University used population data and computer modeling to predict how many people will get uterine cancer -- and how many will die from it -- over the next 30 years. They predict that the number of new uterine cancer cases will increase by over 50% for Black women compared to about 30% for white women by 2050. Elena Elkin, one of the study's authors and a Ph.D.-level researcher at Columbia's Mailman School of Public Health, pointed to an aging population as one major cause of the projected increase. "Like many cancers, uterine cancer is a disease of aging. Another major factor is the increase in overweight and obesity in the U.S. population," she said. Elkin pointed to decreases in hysterectomies -- surgery to remove the uterus -- for conditions like fibroids and endometriosis as another reason uterine cancer rates are increasing. More women are living with their uterus, putting them at risk of developing the disease, she noted. The uterus is a hollow, pear-shaped organ located in a woman's pelvis where a fetus develops and grows. Uterine cancer refers to any cancer that arises in this organ, including endometrial cancer, the most common form. Uterine sarcomas that develop in the muscles or the tissues of the uterus are more rare -- and more fatal. Overall, uterine cancer has an 81% five-year survival rate. "Survival outcomes are generally good, because most cancers are diagnosed at an early stage," Elkin said. Cancer diagnoses rising faster in women, especially those under 50: Report Unfortunately, this is not the case for all. For those diagnosed with more aggressive forms of the disease, five-year survival drops to 20-50%. Black women are already more likely to have aggressive forms and are two times more likely to die from uterine cancer compared to white women, NCI statistics show. The American Association for Cancer Research study projects worsening racial disparities. By 2050, Black women could be three times more likely to die of the disease. "Studies have shown that these disparities are due to delays in diagnosis, barriers to accessing care, and receiving sub-optimal care," Elkin said. Some research has linked chemical hair relaxers to uterine cancer. In the U.S., about 95% of Black women under age 45 have used chemical hair relaxers at least once in their lives. Chemical relaxers have been found to have toxins like formaldehyde, heavy metals, and endocrine disrupting chemicals like phthalates and parabens. Many have been linked to cancer. Although chemical relaxer use has declined significantly in recent years, women who used them at all during their lifetime are still at risk of possible long-term impacts. There are currently no routine screening tests for uterine cancer. People are often diagnosed once they start having symptoms like abnormal vaginal bleeding typically after menopause, pelvic pain and weight loss. "We don't yet have a test that is accurate enough to provide the maximum benefit and minimum harm," Elkin stated. The study model found that if there was an accurate screening test for women at age 55, rates of uterine cancer cases would significantly decrease. Woman has uterine fibroids removed that equaled the size of a 6-month pregnancy "We can use models like this one to evaluate emerging technologies for screening," she said. Although the study's uterine cancer projections are concerning, Elkin said she remains optimistic. She pointed to emerging treatment like immunotherapy and bio marker-based therapies as promising options. Elkin also emphasized targeting risk factors as a way to lower the number of new cases. "Population level changes in overweight and obesity, perhaps through improved access to the current generation of weight loss medications, could lead to reductions in uterine cancer cases in the future," she said. Dr. Adeiyewunmi (Ade) Osinubi is an emergency medicine resident physician at the University of Pennsylvania and is a member of the ABC News Medical Unit.
Associated Press
30 minutes ago
- Associated Press
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
MILAN and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that a total of 38 patients were enrolled in newly diagnosed glioblastoma multiforme (TEM-GBM) study, with 25 patients receiving Temferon. Two patients have been enrolled in the TEM-LT long-term follow-up study, surviving three years from the time of 1st surgery. One of these long-term survivors has not experienced disease progression following Temferon administration and has not required any second-line therapies. The other showed initial signs of disease progression that subsequently stabilized without additional therapeutic intervention. Both these cases suggest possible Temferon-mediated control of disease progression, which warrants further investigation in larger studies. As of the April data cutoff, the survival rate at two years in the GBM trial for unmethylated MGMT (uMGMT) patients remained consistent at 29% with median overall survival holding steady at 17 months. In historical cohorts, uMGMT patients receiving standard of care have shown a two-year survival rate of approximately 14% and a median overall survival of 13 to 15 months. In parallel, the TEM-GU Phase 1 study—designed to enroll 12 patients with genitourinary tumors—has begun recruitment. In this trial, Temferon is administered at a fixed dose of 4 million genetically modified cells per kilogram of body weight—a level previously shown to be safe and well tolerated in the TEM-GBM dose-ranging study. Genenta aims to demonstrate the safety and tolerability of Temferon in patients with Metastatic Renal Cell Carcinoma by year-end. The study is designed to evaluate Temferon in combination with immune checkpoint inhibitors or tyrosine kinase inhibitors to assess the potential for immunologic synergy in this patient population. Further clinical updates will be shared once sufficient patient experience has been gained to support meaningful interpretation. Temferon's mechanism of action is based on the reprogramming of the tumor microenvironment, which promotes the activation and durability of adaptive immune responses. A scientific manuscript demonstrating Temferon's potential to enhance and prolong the durability of CAR-T activity in preclinical murine models of solid tumors has been accepted for publication in Science Translational Medicine. ' For the first time, we show that hematopoietic stem cells can be engineered to durably give rise to myeloid cells that localize to the tumor and reprogram its immune environment. In glioblastoma, this strategy induced a pro-inflammatory shift in macrophages and the emergence of tumor-reactive T cells, offering a promising new avenue for immune engagement against one of the most resistant cancers, ' said prof. Luigi Naldini, co-founder of Genenta Science. ' We are encouraged by the consistent clinical signals emerging from our glioblastoma trial, ' said Pierluigi Paracchi, CEO of Genenta Science. 'T hese findings reinforce our confidence in Temferon's differentiated mechanism and support our commitment to advancing the platform. ' About Genenta Science Genenta Science (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta's first in class product candidate is Temferon™, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow derived myeloid cells and enable a durable and targeted response. Genenta has completed the Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibiting of myeloid induced tolerance, while allowing the induction of T cell responses, potentially breaking immune tolerance. Genenta has initiated a Phase 1/2a metastatic Renal Cell Carcinoma study that will also include a combination with immune checkpoint inhibitors. Genenta's treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics. Forward-Looking Statements Statements in this press release contain 'forward-looking statements,' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'suggest,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the funding provided by the recently acquired Mandatory Convertible Bond, the completion and timing of Genenta's ongoing Phase 1/2a clinical trial for newly diagnosed GBM patients with uMGMT-GBM, its clinical trial for metastatic RCC or any related studies, as well as Genenta's ability to fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in Genenta's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law. This press release discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates or the use for which such product candidates are being studied. Temferon™ is an investigational product candidate for which the effectiveness and safety have not been established. In addition, Temferon™ is not approved for use in any jurisdiction. Genenta Science Media Tiziana Pollio, Mobile: +39 348 23 15 143 E-mail: [email protected]
